A Phase 1 interventional study of SHR-1209 single-site subcutaneous injection and SHR-1209 multiple-site subcutaneous injections in Hypercholesterolemia and Hyperlipidemia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-30.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Hypercholesterolemia with a site in China — 10 open to participants now, 17 under way, 10 of them phase 3. Hypercholesterolemia · China.
Among the 59 studies in Hypercholesterolemia with a site in China, this one is the 46th largest by enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2025, is one of 12 in phase 1, and was the 52nd registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →10 of the 59 studies in Hypercholesterolemia with a site in China are open now. Recruiting first, the newest first:
Beijing Suncadia Pharmaceuticals Co., Ltd · Sites in China
Ages 18–85
Novartis Pharmaceuticals · Sites in China, United States, Austria and 8 more countries
Ages 2–11
Novartis Pharmaceuticals · Sites in China, United States, Argentina and 20 more countries
Ages 6–11
Hasten Biopharmaceutical Co., Ltd. · Sites in China
Ages 18+
Stephen Nicholls · Sites in China, Australia, India and 6 more countries
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 8 · Phase 3 27 · Phase 4 1
First in 2003; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is below the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 207 across the 53 interventional studies, 924 across the 6 observational. Of the 39 that completed or were terminated, 9 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 59 have an industry lead sponsor. The 10 most frequent:
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
Jiangsu HengRui Medicine Co., Ltd. has 5 studies filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
4 of the studies in Hypercholesterolemia with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07930507Phase 3AstraZenecaA Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients | 2027-10-11 |
| NCT05399992Novartis PharmaceuticalsStudy Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD | 2026-11-23 |
| NCT05325034Stephen NichollsGuideline Oriented Approach To Lipid Lowering In Asia-Pacific | 2026-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 59 studies in Hypercholesterolemia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In order to improve the medication convenience and compliance of patients and facilitates in the long-term control of disease condition, it is planned to reduced the number of injections to one per administration. The study aims to compare the safety and pharmacokinetics data to assess feasibility of single-site and multiple-site injection for administration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SHR-1209 single-site subcutaneous injection · Drug: SHR-1209 multiple-site subcutaneous injections
Drug: SHR-1209 single-site subcutaneous injection · Drug: SHR-1209 multiple-site subcutaneous injections
SHR-1209 single-site subcutaneous injection.
SHR-1209 multiple-site subcutaneous injections.
Visual Analog Scale (VAS) was used to evaluate the injection site pain of single-site subcutaneous injection of SHR-1209.
Time frame: After injection in day 1 and day 57.
Visual Analog Scale (VAS) was used to evaluate the injection site pain of multiple-site subcutaneous injections of SHR-1209.
Time frame: After injections in day 1 and day 57.
Area under the curve (AUC0-56).
Time frame: After injection in day 1 up to day 56.
Peak time (Tmax) of SHR-1209.
Time frame: After injection in day 1 up to day 56.
Peak concentration (Cmax) of SHR-1209.
Time frame: After injection in day 1 up to day 56.
Subjects' preferred method of SHR-1209 administration between the tested injection regimens.
Time frame: Day 68.
Incidence and severity of adverse events (AEs).
Time frame: From Day 1 to Day 169.
Incidence and severity of serious adverse events (SAEs).
Time frame: From Day 1 to Day 169.
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Mar 2025 to primary completion in Nov 2025, 7 months.
Of 41 industry-sponsored phase 1 interventional studies under Hypercholesterolemia, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 7 months is close to that.
Counting every sponsor, half of 46 studies reached it within 7 months; a quarter within 2 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Recaticimab
Jiangsu HengRui Medicine Co., Ltd. →